Yissum biotech unit raises $3m from Chinese investors

Hebrew University's Integra Holdings has received $3 million from Guangxi Wuzhou Pharmaceutical.

Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, has received a $3 million investment from China's Guangxi Wuzhou Pharmaceutical Group. The funds raised will be used to advance Integra Holdings existing portfolio companies and to create new companies, based on promising projects originating from the Hebrew University.

Integra Holdings, founded by Yissum in 2012, has a portfolio of companies in such therapeutic areas such as oncology, Alzheimers disease, infectious diseases, analgesia and inflammation. The innovative products developed by the portfolio companies range in maturity from pre-clinical stages of development, through clinical stages, to registration. Currently, the portfolio includes Ayana, Atox Bio, Avraham Pharmaceuticals, Lipomedix, Tiltan Pharma, Lipocure and HIL Applied Medical, in addition to two new companies, which are now being established and develop products with expected short time to market.

Investors in Integra Holdings are Invatech Holdings, a group of private US and Israeli investors; Halman-Aldubi Provident and Pension Fund; the Funds of Teaching Personnel and the HUJI Provident Fund. Integra Holdings has raised a total of $12 million to date.

We are pleased to have Guangxi Wuzhou Pharmaceutical Group join as an investor that can also assist us in introducing biotech products and technologies based on research performed at the Hebrew University to the Chinese market, said Yissum CEO and Integra chairman Yaacov Michlin. After only two years since its inception, Integra Holdings has obtained an investment at twice its original valuation.

Integra Holdings CEO Dr. Liana Patt said, We welcome Guangxi Wuzhou Pharmaceutical Groups investment and vote of confidence in the therapeutic products of our exclusive companies and our unique model of advancing cutting edge science and innovation towards commercial realization. We look forward to using this investment to advance products currently in the pipeline of our portfolio companies, and forming new companies based on the Hebrew University's most promising inventions in the field of life science.

This investment was made possible through the local Chinese contacts of the Lakers Holdings Group. Guangxi Wuzhou Pharmaceutical Group Co. Ltd. is a subsidiary of the Guangxi Wuzhou Zongheng Group, a Chinese investment holdings company.

Published by Globes [online], Israel business news - www.globes-online.com - on December 8, 2014

Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Twitter Facebook Linkedin RSS Newsletters Israel Business Conference 2018